SCHEMBL5110030

SCHEMBL5110030

Clc1ccc(-c2cncc(Br)c2)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.48
KMT2A Q03164 1/20 0.44
CYP2A6 P11509 2/20 0.42
CHRNB1 P11230 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNB3 Q05901 1/20 0.41
CTSA P10619 1/20 0.40
HSD11B1 P28845 2/20 0.40
NPC1 O15118 2/20 0.39
HPGD P15428 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
SRD5A2 P31213 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5888962 0.83 CYP2A6 (0.40) KMT2ACYP2A6NPC1HPGDRAB9A
SCHEMBL4771 0.80 CYP2A6 (0.47) KMT2ACYP2A6CTSANPC1RAB9A
SCHEMBL28504263 0.79 CSNK2A1 (0.55) CYP2A6PTK2
SCHEMBL21201466 0.78 ADH5 (0.52) RAB9ASRD5A2TSHR
SCHEMBL5116017 0.77 CYP2A6 (0.52) CYP2A6PTK2
SCHEMBL21201361 0.76 DHODH (0.48) KMT2ACTSANPC1HPGDRAB9A
SCHEMBL32670439 0.75 AHR (0.57) AHRHSD11B1NPC1HPGDRAB9A
SCHEMBL28503202 0.75 CYP2A6 (0.39) KMT2ACYP2A6PTK2
SCHEMBL9413208 0.75 CSNK2A1 (0.46) AHRCHRNB1CHRNB2CHRNB4CHRNA3
SCHEMBL16143069 0.74 AHR (0.52) AHRKMT2AHSD11B1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442694-B2 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC (US) 2008-10-28 US disclosed
EP-1551843-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 US disclosed
WO-2004024729-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER PRODUCTS INC. (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders DBH, CHRNA6, DDT AHR 457/4885KMT2A 2103/4885CYP2A6 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.